4-17 Watchlist 

 

Markets ended flat today despite bad unemployment numbers, airline bailouts, and poor housing data. Futures moved on optimism as Trump speaks out about a reopen strategy and addresses Covid-19 treatments.    

 

ATOS- spiked over 100 percent pre market as they announced a new drug development program called Covid-19 HOPE. The program uses a novel combination of two drugs that have been previously approved by the FDA for other diseases. This created a gap up to multi-month highs. Massive volume came in on this news as well. I’ll be watching to see if it can hold $2.00 support and a push towards todays highs will be watched closely as it can’t hold $3.00ish breakouts well.

 

RVP- from what I see this stock is up for no particular reason but it’s in my ideal price range and breakout pattern. $2-4 are my favorite price ranges to buy and its breaking out just shy of $3.00 as that’s a multi-year high. I’ll monitor volume and movement past $3.00 to buy. 

 

TRNX- is a stock priced under my ideal buying range but this thing moved an impressive 100+ percent on news that they decided not to pursue a reverse stock split. The stock soared over 124% in afternoon trading with volume hitting nearly 600 million compared to its average. This fundamentally has no really chart pattern to follow but I’ll watch anything thats willing to mover this much in a day.

 

MBRX- held a conference call to discuss Covid-19 potential for a drug candidate today getting shares to trade higher even before the call took place. This stock hasn’t moved much from its big gap up a few days ago but its holding its gains. I’ll keep an eye out for continued volume and a breakout to and past $2.00 since that’s its next level to break. This stock has a lot of chatter so the is a good sign as investors are interested. If it opens red tomorrow this will be a no buy. 

 

THMO- announced today that on Wednesday April 15th, following submission of notification to the U.S. Food and Drug Administration (FDA), they received the necessary acknowledgement letter which provided confirmation that the ThermoGenesis' SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit has been appropriately validated. This skyrocketed the stock over 70 percent before consolidating. This is a hard buy as it’s mid range, caught between todays highs and the lows from yesterday which was just under $5.00. Ideally I’d like to see a push towards $9.00 where it fell short of breaking. The spread looks a little wide at about .20 cents so if I look to buy I’ll consider that as well.